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INTRODUCTION
Neurofibromatosis type 1 (NF1), also known as
von Recklinghausen’s disease, is an autosomal domi-
nant disease with complete penetrance and extremely
variable expression ; the incidence is approximately
of 1 in 4000 live births (1). The predominant clinical
hallmarks of NF1 are cafè-au-lait macules, neurofi-
bromas, Lisch nodules of the iris and axillary freck-
ling. Other clinical manifestations are abnormalities
of the cardiovascular, gastrointestinal, renal and
endocrine systems, facial and body disfigurement,
cognitive deficit, and malignancies of the peripheral
nerve sheath and central nervous system (2). The
NF1 gene on chromosome 17q11.2 spans more than
350 kb of genomic DNA and contains 60 exons (1).
The NF1 gene product neurofibromin is a GTPase
activating protein for members of p21ras (Ras) pro-
tein family. Since neurofibromin negatively regu-
lates Ras output by accelerating the conversion of
active Ras-GTP to inactive Ras-GDP, loss of neurofi-
bromin function leads to downstream cell growth
activation (3). Recent findings report that NF1 prod-
uct modulates also protein kinase B (Akt), an im-
portant regulator of cell proliferation and survival
(4).
Pulmonary artery hypertension (PAH) is a dis-
ease of the small pulmonary arteries characterized
by vessel proliferation and vessel wall remodelling.
It results in a progressive increased in pulmonary
vascular resistance and, ultimately in right ventricu-
lar failure and death. A diagnosis of primary (or idi-
opatic) pulmonary artery hypertension (PAH) is
made when no known risk factors or other causes
CASE REPORT
Type 1 neurofibromatosis complicated by pulmonary
artery hypertension : a case report
Sara Simeoni1, Antonio Puccetti2, Marco Chilosi3, Elisa Tinazzi1, Daniele Prati4,
Roberto Corrocher1, and Claudio Lunardi1
1Section of Internal Medicine, Department of Clinical and Experimental Medicine, University of
Verona ; 2Institute G. Gaslini and Department of Experimental Medicine, University of Genova, Italy ;
3Department of Pathology, University of Verona ; and 4Cardiology Unit, University Hospital, Verona,
Italy
Abstract : We describe the case of a patient with neurofibromatosis type 1 (NF1) compli-
cated by severe pulmonary aterial hypertension (PAH) ; only seven cases have been re-
ported on this association so far, and PAH seems to be related to the vascular involve-
ment of neurofibromatosis. The histology of our patient’s lung tissue showed thickening
of arteries and veins by medial and/or intimal hypertrophy and fibrosis. In order to ex-
clude a familiar PAH, the analysis of the bone morphogenetic protein receptor 2 gene was
carried out, but no mutations were found.
On the basis of histological findings and of the results of genetic study we believe that PAH
was a complication of NF1 in our patient and we suggest to screen patients with NF1 for
the presence of PAH by means of trans-thoracic echocardiogram. J. Med. Invest. 54 : 354-358,
August, 2007
Keywords : neurofibromatosis type 1, pulmonary artery hypertension, bone morphogenetic protein receptor 2
Received for publication May 25, 2007 ; accepted July 18, 2007.
Address correspondence and reprint requests to Claudio Lunardi,
MD, Section of Internal Medicine, Department of Clinical and
Experimental Medicine, University of Verona, Policlinico GB
Rossi, Piazzale LA Scuro, 37134 Verona, Italy and Fax : +39-045-
580111.
The Journal of Medical Investigation Vol. 54 2007
354
are identified (5). It is a progressive disease that
usually leads to death within 5 years from the di-
agnosis.
Familial pulmonary hypertension is a rare (6% of
all cases) autosomal dominant disorder with reduced
penetrance, that has been mapped to a 3-cM re-
gion on chromosome 2q33. It is characterized by
monoclonal plexiform lesion on proliferating endo-
thelial cells. The disease can occur from infancy
throughout life (6). Mutations in the gene encod-
ing for the bone morphogenetic protein type II re-
ceptor (BMPR2) have been identified in 72% of af-
fected families and 26% of apparently sporadic cases.
The mutations are widely dispersed throughout the
gene (7). BMPs are members of the transforming
growth factor (beta) superfamily and affect intra-
cellular signalling via Smads and mitogen-activated
protein kinases (8).
We report here the case of a patient with von
Recklinghausen disease complicated by severe PAH.
The analysis of the BMPR2 gene did not show the
presence of any mutation.
CASE REPORT
A 51-year-old Caucasian woman was admitted to
our hospital because of progressive dyspnea on
exertion and hyposthenia (NYHA class III). She
had a history of hypertension since the age of 20.
Physical examination showed many cutaneous
neurofibromas on her trunk, and multiple café au
lait spots, the biggest one (4 cm) on her left wrist.
She had neither peripheral or central cyanosis nor
clubbing. Her blood pressure was 180/105 mm Hg
and heart rate 110 beats/min ; there were inspira-
tory crackles at the right lung and a raised jugular
venous pulse. Examination of the heart was normal,
the liver was palpable at the costal margin and there
was a swelling on the right clavicle region.
Laboratory investigations revealed high ESR (57
mm/Ih ; nv 35) and CRP (37 mg/L nv 5). Full
blood count showed iposideremic microcytic anae-
mia (Hb 9,2 gr/dl, MCV 74 fl, MCH 24 pg). Autoan-
tibodies were negative ; liver and renal functions
and coagulation tests were normal. Serologic test-
ing for HIV was negative. Arterial blood gas ten-
sions (on room air) were as follows : PH 7,43, PCO2
27 mmHg, PO2 72 mmHg, HCO3 18 mmol/L, 02
Sat 90%.
Neck ultrasonography showed a mass of 5 cm at
the right sovraclavear region : the needle biopsy of
the mass was not diagnostic. Chest X-ray showed
bilateral pleural effusion ; chest computed axial to-
mography showed also two nodular lesions with
irregular margins at the basal region of the right
lung with pleural infiltration and a large mass in
upper mediastinum. Bronchoscopy was negative.
An abdomen ultrasonography was normal. A trans-
thoracic echocardiogram revealed concentric hy-
pertrophy of left ventricle, enlarged left atrium (48
mm), interventricular septum of 13 mm and a right
ventricular systolic pressure of 35 mmHg (the peak
of gradient through a mild tricuspid regurgitation
was 30 mmHg + 5 mmHg of right atrial pressure, by
the normal size of a collapsing vena cava, were added
to estimate right ventricular systolic pressure).
The patient was unable to carry out the spiromet-
ric test.
Biopsy of the mediastinum mass was compatible
with schwannoma. The morphological examination
of pulmonary tissue was consistent with pulmonary
hypertension. The main histopathological features
included the presence of focal areas of necrosis,
the occurrence of numerous alveolar macrophages
containing hemosiderin, and a diffuse alteration of
vessel walls. Both arteries and veins appeared thick-
ened by medial and/or intimal hypertrophy and fi-
brosis (Fig. 1). Infiltration of S100+ neurofibroma-
tosis cells was not evident.
On the basis of the histopathological findings and
of the worsening of dyspnoea, after two months we
performed a second echocardiogram, that showed
severe dilation of right chambers, with moderate tri-
cuspid regurgitation, dilatation of vena cava and se-
vere right ventricular systolic pressure (115 mmHg).
A cardiac catheterization confirmed the pres-
ence of severe high PAH (108/39 mmHg ; mean,
65 mmHg), mean pulmonary wedge pressure 11
mmHg. After PGI2 infusive test (vasoreactivity test-
ing), pulmonary vascular resistance remained un-
changed.
Plasma N-terminal pro-B type natriuretic peptide
(proBNP) level was 12,6 pmol/l (nv14,8 pmol/L).
However its levels markedly increased after three
and nine months : 40,8 pmol/l and 472 pmol/l re-
spectively) ; cardiac troponin T was normal.
Since the patient’s grandmother died of lung fail-
ure, the genetic analysis of BMPR2 was carried out
in order to exclude a familiar PAH.
Based on the diagnosis of pulmonary hyperten-
sion, she was started on diuretics, warfarin and
bosentan therapy (62,5 mg twice day for 4 weeks
and then 125 mg twice daily). NYHA class as well
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as the 6 minutes walking test remained stable for
nearly two and half years but recently, because of
worsening of dyspnoea, sildenafil therapy has been
introduced.
Analysis of the BMPR2 gene
DNA was extracted from 10 ml of whole-blood
with Puregene Genomic DNA purification kit (GEN-
TRA systems, Minneapolis, USA) after patient’s in-
formed consent was obtained. Exons 1 to 13 of
BMPR2 gene were amplified by polymerase chain
reaction (PCR) from 100 ng of genomic DNA (Gene-
amp High Fidelity PCR System Kit, Applied Bio-
system, California, USA). The sequence of the prim-
ers used has been already reported elsewhere (6).
Since we had some difficulties in amplifying exon 12,
we wanted to confirm the data obtained by cDNA
synthesis. To this aim, RNA was extracted from
peripheral blood cells using TriReagent extraction
kit (Sigma Corporation, St Louis, Missouri, USA)
and retrotranscribed with the SuperScipt III first-
Strand Synthesis System (Invitrogen, Groningen,
The Netherlands) using oligo(dt) primers. cDNA
was then amplified with the appropriate primers.
BMPR2 cDNA was purified with QIAquick gel ex-
traction kit (QIAGEN).
The PCR fragments obtained from genomic DNA
and cDNA were sequenced using MWG Biothec
service (Ebersberg, Germany) and compared with
the published sequence of the gene and of cDNA.
We did not find any mutation in the exons 1 to 13
of the BMPR2 gene.
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Fig. 1. Pulmonary artery with medial hypertrophy and marked intimal fibrosis.
(A) Anti-cytokeratin immunostaining (arrow). (B) Alpha-smooth-muscle actin and (C) trichrome staining.
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DISCUSSION
We report the case of a patient with neurofibro-
matosis type 1 and PAH. Only seven cases of PAH
in von Recklinghausen’s disease have been reported
so far (9-13). In all reports PAH seems to be re-
lated to the vascular involvement of neurofibroma-
tosis although histology was described only in one
case.
In our patient all the conditions associated with
PAH such as connective tissue diseases, chronic
lung disease, congenital or acquired heart diseases,
HIV infection, drug and toxins, hemoglobinopathies,
myeloproliferative disorders, thromboembolism were
excluded. Vasculopathy associated to neurofibro-
matosis was the probable cause of PAH, however
we wanted to exclude the possibility of mutations
in the BMPR2 gene since there was a suspected
case of PAH in her grandmother. Indeed in the
past year mutations in the BMPR2 gene have been
identified in a high proportion of cases of familial
and sporadic PAH. BMP type II receptor is located
in lipid rafts, including caveolae, of pulmonary en-
dothelium in vivo and in vitro (14). Caveolae are
vescicular organelles that are particularly abundant
in cells of cardiovascular system including endo-
thelial cells, smooth muscle cells and fibroblasts
(4). Caveolin knockout mice display dramatic ab-
normalities in the cardiovascular system, such as
pulmonary hypertension and cardiac hypertrophy
(15). Neurofibromin, the protein encoded by the
NF1 gene has been detected in the endothelial cell
layer of rat cerebral vessels, renal arteries, and
aorta by immunohistochemistry. Neurofibromin ex-
pression was also detected in smooth muscle layer
of the aorta (16). Recently some authors have re-
ported that neurofibromin modulates Akt, an im-
portant regulator of cell proliferation and survival,
and binds to caveolin-1 (4). Therefore the interplay
of neurofibromin, caveolin and akt may play a piv-
otal role in the pathogenesis of PAH in patients
with NF1.
In conclusion, based on the histological findings
of the lung tissue and on the genetic analysis of
BMPR2, we think that PAH was a complication of
NF1 in our patient and suggest that patients with
NF1 need to be evaluated with trans-thoracic echo-
cardiogram for the presence of PAH, even if it has
low sensibility to screen initial forms.
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